Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Generic Drugs Research and Development Strategies Regulation

Complex Generics: Pre-Competitive Research Collaborations To Get US FDA Funding Boost

  • Analysis

Executive Summary

Center for Research on Complex Generics will be similar to the Critical Path Institute; training sessions for industry could begin in January.

You may also be interested in...



Generic Drug Bioequivalence Study Interruptions Not Just A Coronavirus Problem

US FDA should create a policy to help save troubled studies, because failure can kill generic development programs, Lachman Consultants’ Michelle Ryder suggests.

Complex Generics May Need New Communications Options In GDUFA III

US FDA and complex generic sponsors need a way to talk about reference product and other changes once the pre-submission meetings pathway is exhausted.

Rare Disease Cures Accelerator Expected To Drive Lots Of Development – Eventually

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
Generic Drugs Research and Development Strategies Regulation
UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By